Guidance and quality standards Awaiting development

Skip to filtersSkip to results

Skip to results

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme

Showing 326 to 342 of 342

TitleType
Vilobelimab for treating COVID 19 TS ID 11815Technology appraisal guidance
Virtual Wards for COPD exacerbationsMedical technologies guidance
Virtual Wards for Heart FailureMedical technologies guidance
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable TS ID 10266Technology appraisal guidance
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over TS ID 11974Technology appraisal guidance
Vosoritide for treating achondroplasia in children TSID 12001Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Technology appraisal guidance
Vulnerable populations: strategies for tackling inequalitiesQuality standard
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952Technology appraisal guidance
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments TSID 11915Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998Technology appraisal guidance
Zuranolone for treating severe postnatal depression ID6431Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All